Recipharm (RECI B)

Executive Summary

Recipharm is a leading global contract development and manufacturing organization (CDMO) headquartered in Paris, France, with a track record since 1995. The company offers integrated services spanning oral solids, sterile injectables (fill-finish), and biologics, enabling pharmaceutical clients to accelerate drug development from molecule to market. As a private entity listed on a smaller exchange (ticker: RECI B), Recipharm has established itself as a reliable partner in the pharma outsourcing space, benefiting from the growing trend of drug developers outsourcing manufacturing to reduce costs and improve flexibility. The company's comprehensive capabilities across multiple dosage forms and its global footprint position it well to capture demand from both small biotechs and large pharma companies. Looking ahead, Recipharm is expected to continue its growth trajectory by expanding its capacity, particularly in high-demand areas like biologics and sterile manufacturing. The company's financial performance is tied to the overall health of the pharmaceutical outsourcing market, which remains robust amid increasing R&D spending and the need for specialized manufacturing expertise. Despite being private, Recipharm's ticker suggests some public trading, allowing investors to track its progress. Key drivers include strategic partnerships, facility expansions, and the ability to win new contracts from a diversified client base.

Upcoming Catalysts (preview)

• Q2 2026Capacity expansion announcement (e.g., new biologics facility)75% success
• Q3 2026Major contract win with a top-20 pharmaceutical company65% success
• Q1 2027Release of annual financial results or strategic update90% success